Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Scientific Reports
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. scientific reports
  3. articles
  4. article
CD49a+ NK cells promote M2 polarization and are associated with poor pathological response in NSCLC
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 12 June 2026

CD49a+ NK cells promote M2 polarization and are associated with poor pathological response in NSCLC

  • Xin Li1,2,3,4,5 na1,
  • Zelin Zhao1,2,3,7 na1,
  • Weihong Zhang1,2,3,4,6 na1,
  • Meng Wang1,2,3,8,
  • Siyuan Zhang1,2,3,4,5,
  • Nan Dong1,2,3,4,5,
  • Wenwen Yu1,2,3,4,5,
  • Yang An1,2,3,7,
  • Xiubao Ren1,2,3,4,5,6,
  • Hua Zhao1,2,3,7 &
  • …
  • Yu Zhang1,2,3,8 

Scientific Reports (2026) Cite this article

  • 145 Accesses

  • Metrics details

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Subjects

  • Cancer
  • Immunology
  • Oncology

Abstract

Natural killer (NK) cells are key for tumor immune defense. Tissue-resident NK subsets often differ from classical CD16+ NKs and can be immunosuppressive. The exact traits and mechanisms of these tissue-resident NKs in the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC) are still unclear. This study aimed to comprehensively analyze NK cells in the NSCLC tumor microenvironment to identify distinct tissue-resident subsets, assess their clinical relevance, and investigate their functional properties and underlying mechanisms in shaping immunosuppression. We identified CD49a+ NK cells as a distinct tissue-resident subset in non-small cell lung cancer surgical specimens. Single-cell RNA sequencing revealed that this subset is associated with poor pathological response to neoadjuvant therapy. The abundance of CD49a+ NK cells negatively correlates with the formation of tertiary lymphoid structures (TLS). These cells exhibit an altered phenotype, characterized by upregulated immune checkpoint genes, downregulated cytotoxicity-related genes, and uniquely elevated expression of CSF-1. This CD49a+ NK cell subset is functionally linked to driving M2 macrophage polarization, and M2 polarization tends to inversely correlate with TLS density. Our findings indicate that CD49a+ NK cells contribute to the induction of M2 macrophage differentiation within the tumor stroma and are unfavorable for TLS formation. Our findings identify a specific CD49a+ tissue-resident NK cell subset that fosters an immunosuppressive microenvironment in NSCLC by impairing TLS formation and driving M2 macrophage polarization, a mechanism that likely contributes to adverse responses to neoadjuvant therapy.

Acknowledgements

The research team would like to express its profound gratitude to our colleagues in the Department of Pathology, whose expertise was instrumental in making accurate pathological diagnoses and preparing tumor sections. We are also deeply thankful to all patients who generously agreed to take part in this study, as their participation has been the cornerstone of our investigation.

Funding

The study was generously funded through grants from the National Natural Science Foundation of China, specifically with allocations numbered No.82473329, No.82372779, as well as through the Joint Funds of the Tianjin Natural Science Foundation, under grant number No.25JCLMJC00120.

Author information

Author notes
  1. These authors contributed equally: Xin Li, Zelin Zhao and Weihong Zhang.

Authors and Affiliations

  1. National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Xin Li, Zelin Zhao, Weihong Zhang, Meng Wang, Siyuan Zhang, Nan Dong, Wenwen Yu, Yang An, Xiubao Ren, Hua Zhao & Yu Zhang

  2. Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Xin Li, Zelin Zhao, Weihong Zhang, Meng Wang, Siyuan Zhang, Nan Dong, Wenwen Yu, Yang An, Xiubao Ren, Hua Zhao & Yu Zhang

  3. Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Xin Li, Zelin Zhao, Weihong Zhang, Meng Wang, Siyuan Zhang, Nan Dong, Wenwen Yu, Yang An, Xiubao Ren, Hua Zhao & Yu Zhang

  4. Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Xin Li, Weihong Zhang, Siyuan Zhang, Nan Dong, Wenwen Yu & Xiubao Ren

  5. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Xin Li, Siyuan Zhang, Nan Dong, Wenwen Yu & Xiubao Ren

  6. Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Weihong Zhang & Xiubao Ren

  7. Department of Cancer Molecular Immunology, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Hexi District, Tianjin, 300060, China

    Zelin Zhao, Yang An & Hua Zhao

  8. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, 45 Binshui Road, Tiyuanbei, Hexi District, Tianjin, 300060, China

    Meng Wang & Yu Zhang

Authors
  1. Xin Li
    View author publications

    Search author on:PubMed Google Scholar

  2. Zelin Zhao
    View author publications

    Search author on:PubMed Google Scholar

  3. Weihong Zhang
    View author publications

    Search author on:PubMed Google Scholar

  4. Meng Wang
    View author publications

    Search author on:PubMed Google Scholar

  5. Siyuan Zhang
    View author publications

    Search author on:PubMed Google Scholar

  6. Nan Dong
    View author publications

    Search author on:PubMed Google Scholar

  7. Wenwen Yu
    View author publications

    Search author on:PubMed Google Scholar

  8. Yang An
    View author publications

    Search author on:PubMed Google Scholar

  9. Xiubao Ren
    View author publications

    Search author on:PubMed Google Scholar

  10. Hua Zhao
    View author publications

    Search author on:PubMed Google Scholar

  11. Yu Zhang
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Xiubao Ren, Hua Zhao or Yu Zhang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics statement

The research adhered to stringent ethical guidelines and received the stamp of approval from the Tianjin Medical University Cancer Institute and Hospital’s Ethics Committee. Each participant in the study was thoroughly briefed and gave their explicit consent in writing.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Zhao, Z., Zhang, W. et al. CD49a+ NK cells promote M2 polarization and are associated with poor pathological response in NSCLC. Sci Rep (2026). https://doi.org/10.1038/s41598-026-57649-1

Download citation

  • Received: 21 February 2026

  • Accepted: 08 June 2026

  • Published: 12 June 2026

  • DOI: https://doi.org/10.1038/s41598-026-57649-1

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Tertiary lymphoid tissue
  • Tissue resident NK
  • Anti-PD1
  • Non-small cell lung cancer
  • M2 macrophage
Download PDF

Advertisement

Explore content

  • Research articles
  • News & Comment
  • Collections
  • Subjects
  • Follow us on Facebook
  • Follow us on X
  • Sign up for alerts
  • RSS feed

About the journal

  • About Scientific Reports
  • Contact
  • Journal policies
  • Guide to referees
  • Calls for Papers
  • Editor's Choice
  • Journal highlights
  • Open Access Fees and Funding

Publish with us

  • For authors
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Scientific Reports (Sci Rep)

ISSN 2045-2322 (online)

nature.com footer links

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer